This poster provides the results of ex vivo experiments using a novel inhibitor of DHODH, to investigate its potential as a treatment for AML. It was presented at the 2019 EHA meeting in Amsterdam
EHA 2019 poster: PTC299 is a novel dihydroorotate dehydrogenase (DHODH) inhibitor for use in treatment of acute myeloid leukemia (AML)
Register here to access the content on the site
MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
MED-ALL-CORP-2200029 | December 2022
COMING SOON
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.